Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
New York University School of Medicine
Headquarters: New York, NY, United States of America
Website: http://www.med.nyu.edu
Year Founded: 1841
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Sep 3, 2024
Discovery & Translation
Eyes on the target: Drug discovery’s new paradigm
Back to School 2024: Can biotech write a more successful playbook for translating from target to product?
BioCentury | Feb 5, 2024
Guest Commentary
The elliptical billiard balls of FDA policy
Chevron deference has, in essence, rigged the game for FDA. Now more than ever, the agency needs modernized, defensible policies
BioCentury | Feb 17, 2022
Management Tracks
New leadership for Merck’s human health business
Plus new CEOs at Renibus and Indapta, updates from Milestone, Briacell and more
BioCentury | Jul 30, 2021
Distillery Therapeutics
Inhibiting the H3K36me2 pathway for a pediatric brain cancer subtype
DISEASE CATEGORY: Cancer
INDICATION: Brain cancer Targeting the NSD1/NSD2-H3K36me2-PSIP1/HDGF2 pathway could treat diffuse intrinsic pontine glioma (DIPG) harboring the histone H3K27M driving
INDICATION: Brain cancer Targeting the NSD1/NSD2-H3K36me2-PSIP1/HDGF2 pathway could treat diffuse intrinsic pontine glioma (DIPG) harboring the histone H3K27M driving
BioCentury | Jul 30, 2021
Distillery Therapeutics
Bacterial hydrogen sulfide biogenesis inhibitors identified as antibiotic potentiators
DISEASE CATEGORY: Infectious disease
INDICATION: Staphylococcus; Pseudomonas Three indole-based inhibitors of bacterial cystathionine γ-lyase, an enzyme involved in hydrogen sulfide
INDICATION: Staphylococcus; Pseudomonas Three indole-based inhibitors of bacterial cystathionine γ-lyase, an enzyme involved in hydrogen sulfide
BioCentury | Jan 15, 2021
Product Development
Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C
Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy and includes machine-learning tools for image-based pathology. The New
BioCentury | Jan 8, 2021
Product Development
Caplan sees a host of bioethical turning points coming out of the pandemic
Bioethicist Arthur Caplan on how the post-pandemic world will see changes from patient consent to DSMBs to data dissemination
BioCentury | Oct 31, 2020
Regulation
Expanding access to COVID-19 vaccines
Imminent release of interim data will force FDA to make tough decisions about pre-approval access to COVID-19 vaccines
Items per page:
1 - 10 of 156